Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

SML2613

Sigma-Aldrich

Secnidazole

≥98% (HPLC)

Synonym(s):

1-(2-methyl-5-nitro-1H-imidazol-1-yl) propan-2­ol, 1-(2­Hydroxypropyl)-2-methyl-5-nitroimidazole, SYM-1219

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C7H11N3O3
CAS Number:
3366-95-8
Molecular Weight:
185.18
MDL number:
MFCD00864656
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

H2O: 2 mg/mL, clear (warmed)

storage temp.

2-8°C

InChI

1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3

InChI key

KPQZUUQMTUIKBP-UHFFFAOYSA-N

Biochem/physiol Actions

Secnidazole is a nitroimidazole anti-microbial selective against many anaerobic Gram-positive and Gram-negative bacteria and protozoa. It has been approved for the treatment of bacterial vaginosis. Secnidazole is a prodrug, whose nitro group is reduced by bacterial enzymes to radical anions that interfere with bacterial DNA synthesis.

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

SML2613-VAR:
SML2613-50MG:
SML2613-10MG:
SML2613-BULK:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Helen S Pentikis et al.
Advances in therapy, 33(12), 2229-2241 (2016-10-17)
Bacterial vaginosis (BV) is a serious infection that is the most common vaginal infection in women of childbearing potential. SYM-1219 is a novel, granule formulation containing 2 g of secnidazole that is being developed as a single, oral dose to treat
Melinda A B Petrina et al.
Anaerobe, 47, 115-119 (2017-05-20)
Secnidazole, a 5-nitroimidazole with a longer half-life, is structurally related to metronidazole and tinidazole. For treatment of bacterial vaginosis (BV), secnidazole is a suitable single-dose oral drug having a longer serum half-life than metronidazole. The objective of this study was
Borje Darpo et al.
Journal of clinical pharmacology, 58(3), 286-293 (2017-10-03)
SYM-1219, a novel oral granule formulation of secnidazole, is under development as single-dose treatment for bacterial vaginosis. This 4-way, randomized, crossover study evaluated the effects of SYM-1219 on electrocardiographic (ECG) parameters in 52 healthy subjects. Subjects were administered single doses

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service